Prostate Cancer

High-Potency Vaccine Enter Trials In Those Who Failed Hormone Therapy

Published in Cancer Weekly, May 8th, 2001

Cell Genesys, Inc. (CEGE) announced April 17, 2001, that it has initiated the first in a series of clinical trials of a high potency version of GVAX^R prostate cancer vaccine following encouraging Phase II clinical data recently reported for its first generation product.

The testing of this new high potency product will explore various treatment regimens and will be conducted in prostate cancer patients who have failed standard hormone therapy.

The series of trials is anticipated to involve a total of approximately 40 to 60 patients depending upon the number of treatment regimens tested and will include an evaluation of GVAX prostate...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-05-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry